GlassScriptPhysician profile
Christine Mac
NPI 1104363720
$3,006.47
in general payments reported to CMS, 2019-2025
23 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,532 · 2022: $643 · 2023: $474 · 2024: $24.60 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $691.27 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $374.17 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $255.78 | 2021-2022 | |
| Exact Sciences Corporation | $203.23 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $173.09 | 2023-2025 | Jardiance, Trulicity, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $124.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $115.05 | 2022 | |
| Esperion Therapeutics, INC. | $109.97 | 2022 | |
| Amgen INC. | $76.96 | 2021 | |
| Merck Sharp & Dohme LLC | $72.09 | 2021-2025 | Verquvo |
| Ucb, INC. | $45.89 | 2021 | |
| Hologic Sales and Service, LLC | $36.21 | 2025 | Thinprep 2000 Processor, Aptima |
| Amarin Pharma, INC. | $35.29 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.11 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $26.00 | 2021 | |
| Abbvie INC. | $18.73 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.70 | 2025 | Gvoke Hypopen |
| Ani Pharmaceuticals, INC. | $17.27 | 2025 | Purified Cortrophin Gel |
| Cipher Pharmaceuticals US LLC | $16.41 | 2025 | Spinosad, Natroba |
| Otsuka America Pharmaceutical, INC. | $15.36 | 2025 | Rexulti |
| Bard Peripheral Vascular, INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Mac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.